SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ariella who wrote (1209)9/2/1998 4:56:00 PM
From: crysball  Read Replies (2) of 1491
 
Tamoifen was FDA approved today for Prophylactic use.

An AOL news feature this afternnon indicated the FDA panel 'reluctantly' approved Tamoxifen for breast cancer prophylaxis....but indicated there was uncertainty among the panel about what at risk populations it may apply.

Omer seemed seemed to conclude the driving issue at PARS on the Tamoxifen analogue Phase1 study was cash position? Is this not correct?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News